The progression-free survival (PFS) benefit observed with olaparib maintenance persists after treatment completion in patients with advanced ovarian cancer, according to research published in The Lancet Oncology.
Five-year follow-up data from the phase 3 SOLO1 trial showed a sustained PFS benefit with 2 years of olaparib maintenance, compared with placebo, in patients with ovarian cancer.
“To our knowledge, this report represents the longest follow-up period for a PARP inhibitor in the newly diagnosed advanced ovarian cancer setting and the first demonstration of a progression-free survival benefit with a PARP inhibitor as maintenance monotherapy that extends beyond completion of treatment,” the researchers wrote.
“Although overall survival data are not yet available, the 5-year follow-up results of the SOLO1 trial support the use of maintenance olaparib as a standard of care for women with newly diagnosed ovarian cancer and a BRCA mutation, and suggest that maintenance olaparib can provide long-term remission, and potentially cure, for some patients, so that their life expectancy could approach that of the age-adjusted general population,” the researchers wrote.